This study focuses on uncovering the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in attenuating arterial stiffness in patients with acute coronary syndrome (ACS) and atherosclerosis. This evidence concerns the gene PCSK9 and atherosclerosis.